BD1063

BD1063 is a selective sigma-1 receptor antagonist. It is primarily used in scientific research to study the role of sigma-1 receptors in various physiological and pathological processes.
Chemical Properties[edit]
BD1063 is a chemical compound with the IUPAC name N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethanamine. It has a molecular formula of C15H22Cl2N2 and a molecular weight of 301.26 g/mol.
Pharmacology[edit]
BD1063 acts as a selective antagonist at the sigma-1 receptor, a type of sigma receptor that is involved in the modulation of ion channels, neurotransmitter release, and cell signaling pathways. By blocking the sigma-1 receptor, BD1063 helps researchers understand the receptor's role in various conditions, including neurological disorders, pain, and drug addiction.
Research Applications[edit]
BD1063 is widely used in preclinical studies to investigate the therapeutic potential of sigma-1 receptor antagonists. It has been studied in models of neuropathic pain, depression, and schizophrenia. Additionally, BD1063 has been used to explore the sigma-1 receptor's involvement in cancer and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Safety and Toxicity[edit]
As with many research chemicals, the safety and toxicity profile of BD1063 is not fully established. It is primarily used in controlled laboratory settings, and its effects in humans are not well-documented.
See Also[edit]
- Sigma receptor
- Sigma-1 receptor
- Neuropathic pain
- Depression
- Schizophrenia
- Alzheimer's disease
- Parkinson's disease
References[edit]
External Links[edit]
-
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian